Drugs / BI 11054 CL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02273401 | Jan → Aug 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 11054 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02273401 ↗ |
| Route | Inhaled | “Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat®) of BI 11054 CL” NCT02273401 ↗ |